The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.
Kathy Miller
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech
Expert Testimony - Roche/Genentech
Anne M. O'Neill
No relevant relationships to disclose
Chau T. Dang
No relevant relationships to disclose
Donald W. Northfelt
No relevant relationships to disclose
William John Gradishar
No relevant relationships to disclose
Lori J. Goldstein
Consultant or Advisory Role - Genentech
Ingrid A. Mayer
No relevant relationships to disclose
Adam Brufsky
Consultant or Advisory Role - Genentech
Stuart Hunegs Bloom
No relevant relationships to disclose
Joseph A. Sparano
Consultant or Advisory Role - Genentech
Amye Tevaarwerk
No relevant relationships to disclose
Kevin R. Fox
No relevant relationships to disclose
Carolyn Bennett Hendricks
No relevant relationships to disclose
Ernie P. Balcueva
No relevant relationships to disclose
George W. Sledge
Honoraria - Genentech
Research Funding - Genentech